Log in to save to my catalogue

Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate c...

Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate c...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_05ea3477df904c7e9eba15f0eafa2c79

Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial

About this item

Full title

Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial

Publisher

England: BioMed Central Ltd

Journal title

BMC cancer, 2020-09, Vol.20 (1), p.884-9, Article 884

Language

English

Formats

Publication information

Publisher

England: BioMed Central Ltd

More information

Scope and Contents

Contents

In recent years, there is increasing evidence showing a beneficial outcome (e.g. progression free survival; PFS) after metastases-directed therapy (MDT) with external beam radiotherapy (EBRT) or targeted surgery for oligometastatic hormone sensitive prostate cancer (oHSPC). However, many patients do not qualify for these treatments due to prior int...

Alternative Titles

Full title

Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_05ea3477df904c7e9eba15f0eafa2c79

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_05ea3477df904c7e9eba15f0eafa2c79

Other Identifiers

ISSN

1471-2407

E-ISSN

1471-2407

DOI

10.1186/s12885-020-07386-z

How to access this item